Weekly Dosing Pharmacokinetics

Weekly dosing pharmacokinetics describes the pharmacokinetic profile characteristic of long-acting incretin analogues such as Semaglutide (~1 week half-life) and Tirzepatide (~5 day half-life) that supports once-weekly subcutaneous administration.

The profile requires DPP-4 resistance (typically through Aib substitutions) combined with reversible non-covalent albumin binding (through a fatty-acid side chain). Steady state is reached after approximately five half-lives — four to five weeks for these analogues.